Filing Details

Accession Number:
0001209191-21-041646
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-17 18:40:05
Reporting Period:
2021-06-16
Accepted Time:
2021-06-17 18:40:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Chinook Therapeutics Inc. KDNY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1823197 Alan Glicklich C/O Chinook Therapeutics, Inc.
1600 Fairview Ave. E.
Seattle WA 98102
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-16 20,000 $0.42 20,000 No 4 M Direct
Common Stock Disposition 2021-06-16 20,000 $16.35 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-06-16 20,000 $0.00 20,000 $0.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
222,662 2030-04-21 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.17 to $16.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
  3. The stock option vested as to 25% of the total shares on April 20, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on the vesting date.